The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Phil Nadeau - TD Securities - Analyst
: <_ALACRA_META_ABSTRACT>But nonetheless, Chris, we will start with your vision for Biogen. What is your vision for Biogen over the next five years? How do you
expect Biogen to create shareholder value?
Question: Phil Nadeau - TD Securities - Analyst
: Maybe to dive down a little bit more deeply into two points that you made. I guess the first is on the product portfolio. So your
guidance for this year is for revenue to decline by mid-single-digit percentage. Investors, I think, are keenly focused on when Biogen
could return to growth. Do you think the current product portfolio, both what's on the market and in the late-stage pipeline is
sufficient to return Biogen to growth? Or do you need to look externally?
Question: Phil Nadeau - TD Securities - Analyst
: So in light of the pipeline, what is your thinking on business development? I think when you first came into Biogen, you said essentially
they wouldn't hire me if I wasn't going to do deals. Now it sounds like you're actually more enthusiastic about the pipeline than
maybe you had been in the past. So how much urgency does Biogen feel it needs to add to the portfolio to in-license or acquire
another asset?
Question: Phil Nadeau - TD Securities - Analyst
: One big picture question before we dive into some of the franchises, specifically. It seems like there's a lot of changes going on in
the biopharmaceutical industry these days. We're seeing unprecedented things, for example, coming out of Washington.
You've been in the C-suite for a long time. Could you maybe give us some of your wisdom? How has the industry changed over the
last 10 years? And what hasn't really changed? What continues to be constant?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 03, 2025 / 2:10PM, BIIB.OQ - Biogen Inc at TD Cowen Healthcare Conference
Question: Phil Nadeau - TD Securities - Analyst
: That is very helpful. Maybe to dive into the franchises. LEQEMBI, can you talk about the status of LEQEMBI launch into various markets?
And how do you see the launch progressing?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 03, 2025 / 2:10PM, BIIB.OQ - Biogen Inc at TD Cowen Healthcare Conference
Question: Phil Nadeau - TD Securities - Analyst
: How do you view the current and future competition in Alzheimer's, and is there an opportunity to differentiate LEQEMBI through
initiatives like the subcutaneous version that you mentioned?
Question: Phil Nadeau - TD Securities - Analyst
: We, at TD Cowen, project $3.4 billion in the LEQEMBI revenue in 2030. How does that strike you? Is that conservative, aggressive?
And when do you think ultimately LEQEMBI could begin to contribute to Biogen's topline in a meaningful one?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 03, 2025 / 2:10PM, BIIB.OQ - Biogen Inc at TD Cowen Healthcare Conference
Question: Phil Nadeau - TD Securities - Analyst
: Moving to SKYCLARYS. Can you discuss how the SKYCLARYS launch is progressing here in the US and overseas? And how do you
consider competition, if anything?
Question: Phil Nadeau - TD Securities - Analyst
: Maybe a minute on the MS franchise, what is the outlook for that franchise? Is a modest contraction reasonable in light of all the
competition that is coming? How do you think about resourcing the MS franchise? What is the appropriate amount of marketing
and promotion behind it?
Question: Phil Nadeau - TD Securities - Analyst
: And one last question as we're just about out of time on the R&D portfolio. You mentioned that you feel like there's an opportunity
to rebuild Biogen. What is the optimal structure for an R&D portfolio as you think about that rebuild? And for investors, there's one
pipeline program we should diligence. Which one do you think it is today?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 03, 2025 / 2:10PM, BIIB.OQ - Biogen Inc at TD Cowen Healthcare Conference
Question: Phil Nadeau - TD Securities - Analyst
: Great. With that, we're out of time. I wanted to thank you for an interesting discussion.
| 
